The 2023 NCCN guidelines for the first time recommended KRASG12C targeted drug Adagrasib for the treatment of KRASG12C mutant NSCLC, which is a significant breakthrough for KRAS treatment targets. Here, KRAS is linked to non-small cell lung carcinoma.